Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Andy Hsieh

Viking Obesity Pill Faces Steep Climb Against Lilly's Tirzepatide, Analyst Calls Downtrend Reaction 'Extreme'

Investors appear disappointed with Viking Therapeutics Inc.’s (NASDAQ:VKTX) data from its Phase 2 trial of an obesity pill.

Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst

Viking's Oral Obesity Drug Poised To Gain Ground After Eli Lilly's Orforglipron Setback: Analyst

Viking Therapeutics, Inc. (NASDAQ:VKTX) is pressing ahead in the weight-loss drug race with the launch of its Phase 2 VENTURE-Oral trial to test a daily pill version of VK2735 in obese and overweight adults, a move analysts say could position the company to capitalize on Eli Lilly’s recent setback and…

Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors

Eli Lilly's Rare Weight Loss Data Miss Could Benefit Competitors

On Thursday, Eli Lilly and Co.’s (NYSE:LLY) weight loss rival Novo Nordisk A/S (NYSE:NVO), along with smaller firms, Terns Pharmaceuticals, Inc. (NASDAQ:TERN), Viking Therapeutics Inc. (NASDAQ:VKTX), and Structure Therapeutics Inc. (NASDAQ:GPCR) are trading higher.

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Why Is Cardiff Oncology Stock Trading Lower After Colorectal Cancer Data?

As advancements in cancer treatment continue to evolve, the pursuit of more effective therapies for metastatic colorectal cancer remains a critical focus in the pharmaceutical industry. Cardiff Oncology, Inc. (NASDAQ:CRDF) on Tuesday released data from the ongoing CRDF-004 Phase 2 clinical trial evaluating onvansertib in combination with standard-of-care (SoC) in…

Why Viking Therapeutics, 67% Off Its Recent Highs, Could Still Have An Edge In Obesity

Viking Therapeutics stock remains under pressure, but analysts said Wednesday the company's strategy for its Phase 3 studies could pay off.

Investors Business Daily

Viking Therapeutics Skids Despite 'Rapid' Enrollment In Obesity Pill Study

Viking Therapeutics stock skidded Wednesday despite the "encouraging" speed with which the company enrolled patients in an obesity study.

Investors Business Daily

Viking Therapeutics Just Inked A $150 Million Manufacturing Deal. Here's Why Shares Crumbled.

Viking Therapeutics stock toppled Tuesday after the biotech company inked a $150 million manufacturing deal for its weight-loss drug, VK2735.

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Viking Therapeutics Tumbles As Obesity Competition Sabotages Its Novo Nordisk Beat

Viking Therapeutics Tumbles As Obesity Competition Sabotages Its Novo Nordisk Beat

Viking Therapeutics reported strong weight loss for higher doses of its experimental obesity drug.

Investors Business Daily

Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH

Madrigal Catapults After Novo's Wegovy Proves It's No 'Silver Bullet' In MASH

Madrigal stock catapulted again Friday after Novo Nordisk published not "game-changing" results for its MASH treatment.

Investors Business Daily

Viking Therapeutics Skyrockets After Dealing A Blow To Eli Lilly's Obesity Triplet

Viking Therapeutics Skyrockets After Dealing A Blow To Eli Lilly's Obesity Triplet

Viking Therapeutics stock ramped higher Thursday after the company outlined its weight-loss quad — a blow to Eli Lilly's experimental triple.

Investors Business Daily

Weight-Loss Tizzy: Why Altimmune Surged 23% As Others Tumbled On A New Study

Weight-Loss Tizzy: Why Altimmune Surged 23% As Others Tumbled On A New Study

Biotech stocks Madrigal and Altimmune diverged Monday as Wall Street debated the outcome of a weight-loss study in MASH patients.

Investors Business Daily

The Point At Which IBD Stock Of The Day Eli Lilly Could Become Actionable Again

The Point At Which IBD Stock Of The Day Eli Lilly Could Become Actionable Again

Eli Lilly is Friday's IBD Stock Of The Day. After announcing an acquisition, Eli Lilly stock is bounding off its 50-day moving average.

Investors Business Daily

FibroGen Stock Plunges Under Key Lines As Lead Drug Fails; Why Hope Isn't Lost

FibroGen Stock Plunges Under Key Lines As Lead Drug Fails; Why Hope Isn't Lost

FibroGen's leading drug failed in a final-phase study of Duchenne muscular dystrophy patients on Wednesday, leading FGEN stock to dive.

Investors Business Daily

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

the Food and Drug Administration

Viking Therapeutics

Structure Therapeutics

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Pulmonary Fibrosis

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play